These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37651295)

  • 21. Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review.
    Lin J; Wang S; Wen T; Zhang X
    Int Urol Nephrol; 2022 Sep; 54(9):2305-2316. PubMed ID: 35133574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
    Halvorsen YC; Walford GA; Massaro J; Aftring RP; Freeman MW
    Diabetes Obes Metab; 2019 Nov; 21(11):2496-2504. PubMed ID: 31297965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
    Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
    CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
    Desai M; Yavin Y; Balis D; Sun D; Xie J; Canovatchel W; Rosenthal N
    Diabetes Obes Metab; 2017 Jun; 19(6):897-900. PubMed ID: 28083972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
    Suzuki Y; Kaneko H; Okada A; Itoh H; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Matsunaga A; Ako J; Node K; Yasunaga H; Komuro I
    Cardiovasc Diabetol; 2022 May; 21(1):67. PubMed ID: 35585590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
    Prescrire Int; 2015 Feb; 24(157):33-5. PubMed ID: 25802910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
    Halvorsen YD; Lock JP; Zhou W; Zhu F; Freeman MW
    Diabetes Obes Metab; 2019 Oct; 21(10):2248-2256. PubMed ID: 31161692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
    Siamashvili M; Davis SN
    Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
    Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.